Business Launch of Trastuzumab in US market offers a sizeable opportunity for Biocon & Mylan, says Kiran Mazumdar Shaw Updated : December 03, 2019 09:59 AM IST We do have a growing portfolio of biosimilar antibodies for cancer, said Kiran Mazumdar Shaw, CMD, Biocon. At the moment very much on track to achieve sales target of $ 1 billion for biosimilars by FY22, said Kiran Mazumdar Shaw. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.